


GW_193

Global Summary


%DE = 0.14
 # genes with fdr < 0.2 = 1812 (1003 + / 809 -)
 # genes with fdr < 0.1 = 1429 (808 + / 621 -)
 # genes with fdr < 0.05 = 1250 (716 + / 534 -)
 # genes with fdr < 0.01 = 834 (501 + / 333 -)
 # genes in genesets = 16332

<FC> = 0
 <shrinkage-t> = 0
 <p-value> = 0.1
 <fdr> = 0.86

Profile



Regulated Spots




Global Genelist

Rank	ID	log(FC)	fdr p-value	Description Metagene
1	133	1.28	2e-16 3e-14	1 x 42 adrenomedullin [Source:HGNC Symbol;Acc:259]
2	57016	1.94	2e-16 3e-14	1 x 50 aldo-keto reductase family 1, member B10 (aldose reductase)
3	441282	1.96	2e-16 3e-14	1 x 49 aldo-keto reductase family 1, member B15 [Source:HGNC S]
4	216	-1.71	2e-16 3e-14	50 x 50 aldehyde dehydrogenase 1 family, member A1 [Source:HGNC
5	353322	1.51	2e-16 3e-14	6 x 48 ankyrin repeat domain 37 [Source:HGNC Symbol;Acc:29593]
6	91947	1.44	2e-16 3e-14	4 x 43 arrestin domain containing 4 [Source:HGNC Symbol;Acc:280
7	84707	-1.42	2e-16 3e-14	50 x 48 brain expressed X-linked 2 [Source:HGNC Symbol;Acc:3093
8	650	1.38	2e-16 3e-14	1 x 4 bone morphogenetic protein 2 [Source:HGNC Symbol;Acc:1C
9	664	1.53	2e-16 3e-14	2 x 43 BCL2/adenovirus E1B 19kDa interacting protein 3 [Source:HK
10	684	-2.24	2e-16 3e-14	32 x 1 bone marrow stromal cell antigen 2 [Source:HGNC Symbol;A
11	387695	1.6	2e-16 3e-14	1 x 49 chromosome 10 open reading frame 99 [Source:HGNC Synt
12	149563	1.76	2e-16 3e-14	34 x 23 chromosome 1 open reading frame 64 [Source:HGNC Symbc
13	29113	1.59	2e-16 3e-14	2 x 47 chromosome 6 open reading frame 15 [Source:HGNC Symbc
14	29923	1.72	2e-16 3e-14	4 x 44 hypoxia inducible lipid droplet-associated [Source:HGNC Syr
15	768	1.95	2e-16 3e-14	1 x 6 carbonic anhydrase IX [Source:HGNC Symbol;Acc:1383]
16	972	-1.48	2e-16 3e-14	50 x 1 CD74 molecule, major histocompatibility complex, class II inv
17	1041	2.22	2e-16 3e-14	1 x 46 corneodesmosin [Source:HGNC Symbol;Acc:1802]
18	51200	2.37	2e-16 3e-14	1 x 44 carboxypeptidase A4 [Source:HGNC Symbol;Acc:15740]
19	1363	-1.42	2e-16 3e-14	50 x 7 carboxypeptidase E [Source:HGNC Symbol;Acc:2303]
20	54544	1.43	2e-16 3e-14	1 x 50 cysteine-rich C-terminal 1 [Source:HGNC Symbol;Acc:2987]

Global Geneset Analysis

Rank	GSZ	p-value	#all	Geneset
<i>Overexpressed</i>				
1	18.4	NULL	135	H.Tiss WIRTH_Mucosa
2	12.89	NULL	21	CC cornified envelope
3	11.24	NULL	53	BP keratinocyte differentiation
4	10.84	NULL	42	BP keratinization
5	10.02	NULL	16	GSEA C2ELVIDGE_HIF1A_TARGETS_DN
6	10.02	NULL	572	Disease GUDJ_poriasis up
7	9.69	NULL	76	BP epidermis development
8	9.61	NULL	21	CC desmosome
9	9.11	NULL	16	GSEA C2ELVIDGE_HIF1A_AND_HIF2A_TARGETS_DN
10	9.02	NULL	15	GSEA C2FARMER_BREAST_CANCER_CLUSTER_3
11	8.72	NULL	16	GSEA C2FARMER_BREAST_CANCER_CLUSTER_4
12	8.38	NULL	15	GSEA C2AIGNER_ZEB1_TARGETS
13	7.63	NULL	15	GSEA C2RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_MODERATE
14	7.54	NULL	16	GSEA C2LEONARD_HYPOXIA
15	7.5	NULL	232	Chr Chr 18
16	7.17	NULL	261	miRNA target-mir-333
17	7.17	NULL	15	GSEA C2PRAMONJAGO_SOX4_TARGETS_UP
18	7.13	NULL	10	GSEA C2REACTOME_APOPTOTIC_CLEAVAGE_OF_CELL_ADHESION_P
19	7.04	NULL	16	GSEA C2NAGASHIMA_EGF_SIGNALING_UP
20	6.91	NULL	16	GSEA C2HUPER_BREAST_BASAL_VS_LUMINAL_UP
<i>Underexpressed</i>				
1	-12.16	NULL	51	BP type I interferon signaling pathway
2	-11.17	NULL	15	CC MHC class II protein complex
3	-11.06	NULL	13	GSEA C2BOWIE_RESPONSE_TO_TAMOXIFEN
4	-10.6	NULL	16	GSEA C2ZHANG_INTERFERON_RESPONSE
5	-10.39	NULL	16	GSEA C2JROSEVIC_RESPONSE_TO_IMIQUMOD
6	-10.3	NULL	16	GSEA C2EINAV_INTERFERON_SIGNATURE_IN_CANCER
7	-10.02	NULL	47	BP antigen processing and presentation
8	-10	NULL	10	GSEA C2BOWIE_RESPONSE_TO_EXTRACELLULAR_MATRIX
9	-9.8	NULL	10	GSEA C2GRANDVAUX_IFN_RESPONSE_NOT_VIA_IRF3
10	-9.69	NULL	312	BP immune response
11	-8.9	NULL	417	H.Tiss WIRTH_Immune system
12	-8.81	NULL	31	BP negative regulation of viral genome replication
13	-8.76	NULL	16	GSEA C2MOSERLE_IFNA_RESPONSE
14	-8.58	NULL	16	GSEA C2FARMER_BREAST_CANCER_CLUSTER_1
15	-8.54	NULL	23	CC integral to luminal side of endoplasmic reticulum membrane
16	-8.34	NULL	123	BP defense response to virus
17	-7.83	NULL	6	GSEA C2SANA_RESPONSE_TO_IFNG_UP
18	-7.71	NULL	109	BP response to virus
19	-7.39	NULL	60	BP interferon-gamma-mediated signaling pathway
20	-7.36	NULL	74	BP regulation of immune response

p-values



GW_193

Local Summary

%DE = 0.8
 # metagenes = 29
 # genes = 381
 # genes in genesets = 372



genes with $fdr < 0.1 = 270$ (242 + / 28 -)
 # genes with $fdr < 0.05 = 251$ (226 + / 25 -)
 # genes with $fdr < 0.01 = 232$ (210 + / 22 -)

$\langle r \rangle$ metagenes = 0.89
 $\langle r \rangle$ genes = 0.36

$\langle FC \rangle = 0.58$
 $\langle \text{shrinkage-t} \rangle = 20.42$
 $\langle p\text{-value} \rangle = 0$
 $\langle fdr \rangle = 0.32$

Profile

Spot




Local Genelist

Rank	ID	log(FC)	fdr	p-value	Description
1	133	1.28	2e-16	4e-16	1 x 42 adrenomedullin [Source:HGNC Symbol;Acc:259]
2	57016	1.94	2e-16	4e-16	1 x 50 aldo-keto reductase family 1, member B10 (aldose reductase
3	441282	1.96	2e-16	4e-16	1 x 49 aldo-keto reductase family 1, member B15 [Source:HGNC S
4	664	1.53	2e-16	4e-16	2 x 43 BCL2/adenovirus E1B 19kDa interacting protein 3 [Source:HK
5	387695	1.6	2e-16	4e-16	1 x 49 chromosome 10 open reading frame 99 [Source:HGNC Synt
6	29113	1.59	2e-16	4e-16	2 x 47 chromosome 6 open reading frame 15 [Source:HGNC Symbc
7	29923	1.72	2e-16	4e-16	4 x 44 hypoxia inducible lipid droplet-associated [Source:HGNC Syr
8	1041	2.22	2e-16	4e-16	1 x 46 corneodesmosin [Source:HGNC Symbol;Acc:1802]
9	51200	2.37	2e-16	4e-16	1 x 44 carboxypeptidase A4 [Source:HGNC Symbol;Acc:15740]
10	54544	1.43	2e-16	4e-16	1 x 50 cysteine-rich C-terminal 1 [Source:HGNC Symbol;Acc:2987]
11	9547	1.35	2e-16	4e-16	1 x 46 chemokine (C-X-C motif) ligand 14 [Source:HGNC Symbol;f
12	27065	1.41	2e-16	4e-16	1 x 46 Homo sapiens neuron specific gene family member 1 (NSG1)
13	414325	1.9	2e-16	4e-16	1 x 48 defensin, beta 103B [Source:HGNC Symbol;Acc:31702]
14	1824	2.05	2e-16	4e-16	1 x 48 desmocollin 2 [Source:HGNC Symbol;Acc:3036]
15	1828	1.65	2e-16	4e-16	1 x 48 desmoglein 1 [Source:HGNC Symbol;Acc:3048]
16	1830	1.56	2e-16	4e-16	1 x 48 desmoglein 3 [Source:HGNC Symbol;Acc:3050]
17	30001	1.69	2e-16	4e-16	3 x 47 ERO1-like (S. cerevisiae) [Source:HGNC Symbol;Acc:13280]
18	2152	1.53	2e-16	4e-16	1 x 43 coagulation factor III (thromboplastin, tissue factor) [Source:H
19	2167	-1.4	2e-16	4e-16	1 x 44 fatty acid binding protein 4, adipocyte [Source:HGNC Symbol
20	115572	1.63	2e-16	4e-16	1 x 48 family with sequence similarity 46, member B [Source:HGNC

Local Geneset Analysis

Overexpression

Rank	GSZ	p-value	#in/all	Geneset
1	35.44	NULL	93 / 135	H.Tiss WIRTH_Mucosa
2	30.22	NULL	18 / 21	CC cornified envelope
3	25.52	NULL	128 / 572	Disease GUDJ_pсориазис up
4	23.01	NULL	20 / 42	BP keratinization
5	21.13	NULL	25 / 53	BP keratinocyte differentiation
6	21.04	NULL	13 / 21	CC desmosome
7	20.4	NULL	30 / 76	BP epidermis development
8	15.96	NULL	10 / 16	GSEA C2HUPER_BREAST_BASAL_VS_LUMINAL_UP
9	15.33	NULL	7 / 15	GSEA C2AIGNER_ZEB1_TARGETS
10	13.96	NULL	6 / 15	GSEA C2RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_POORLY_DN
11	12.32	NULL	4 / 10	GSEA C2REACTOME_APOPTOTIC_CLEAVAGE_OF_CELL_ADHESION_P
12	11.4	NULL	7 / 29	BP regulation of proteolysis
13	11.35	NULL	14 / 79	MF serine-type endopeptidase inhibitor activity
14	10.84	NULL	10 / 52	BP negative regulation of endopeptidase activity
15	10.49	NULL	3 / 15	MF interleukin-1 receptor binding
16	10.34	NULL	11 / 19	BP peptide cross-linking
17	10.07	NULL	1 / 4	GSEA C2BUDHU_LIVER_CANCER_METASTASIS_DN
18	9.82	NULL	6 / 14	GSEA C2CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL_UP
19	9.4	NULL	5 / 15	GSEA C2RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_POORLY_DN
20	9.38	NULL	4 / 13	GSEA C2REACTOME_GAP_JUNCTION_TRAFFICKING
21	9.3	NULL	5 / 15	GSEA C2FARMER_BREAST_CANCER_CLUSTER_3
22	9.3	NULL	3 / 12	GSEA C2REACTOME_GAP_JUNCTION_ASSEMBLY
23	9.06	NULL	21 / 82	CC intermediate filament
24	8.96	NULL	5 / 16	GSEA C2FARMER_BREAST_CANCER_CLUSTER_4
25	8.48	NULL	7 / 16	GSEA C2COLDREN_GEFITINIB_RESISTANCE_DN
26	8.3	NULL	31 / 186	MF structural molecule activity
27	8.17	NULL	3 / 15	CC connexon complex
28	7.92	NULL	1 / 6	GSEA C2SEIKE_LUNG_CANCER_POOR_SURVIVAL
29	7.8	NULL	13 / 44	CC keratin filament
30	7.45	NULL	3 / 14	GSEA C2KIM_RESPONSE_TO_TSA_AND_DECITABINE_UP
31	7.43	NULL	3 / 16	GSEA C2HARRIS_HYPOXIA
32	7.41	NULL	4 / 10	GSEA C2FOURNIER_ACINAR_DEVELOPMENT_LATE_UP
33	7.41	NULL	6 / 32	CC cell-cell adherens junction
34	7.3	NULL	6 / 13	BP negative regulation of peptidase activity
35	7.29	NULL	3 / 10	GSEA C2SMID_BREAST_CANCER_ERBB2_UP
36	7.16	NULL	3 / 13	BP intermediate filament cytoskeleton organization
37	7.15	NULL	3 / 8	GSEA C2LIU_CDX2_TARGETS_DN
38	6.99	NULL	4 / 15	GSEA C2ZHANG_IMMORTALIZED_BY_HP31_DN
39	6.99	NULL	3 / 10	GSEA C2NIKOLSKY_BREAST_CANCER_20Q12_Q13_AMPLICON
40	6.91	NULL	5 / 23	MF peptidase inhibitor activity



GW_193

Local Summary

%DE = 0.86
 # metagenes = 17
 # genes = 291
 # genes in genesets = 289



genes with $fdr < 0.1 = 212$ (7 + / 205 -)
 # genes with $fdr < 0.05 = 202$ (7 + / 195 -)
 # genes with $fdr < 0.01 = 160$ (5 + / 155 -)

<r> metagenes = 0.98
 <r> genes = 0.56

<FC> = -0.5
 <shrinkage-t> = -17.47
 <p-value> = 0
 <fdr> = 0.36

Profile

Spot



Local Genelist

Rank	ID	log(FC)	fdr	p-value	Description
1	972	-1.48	2e-16	1e-15	50 x 1 CD74 molecule, major histocompatibility complex, class II inv.
2	3108	-1.6	2e-16	1e-15	50 x 1 major histocompatibility complex, class II, DM alpha [Source:]
3	3109	-1.41	2e-16	1e-15	50 x 1 major histocompatibility complex, class II, DM beta [Source:H]
4	3113	-1.88	2e-16	1e-15	50 x 1 major histocompatibility complex, class II, DP alpha 1 [Source:]
5	3122	-1.65	2e-16	1e-15	50 x 1 major histocompatibility complex, class II, DR alpha [Source:]
6	5920	-1.43	2e-16	1e-15	48 x 1 retinoic acid receptor responder (tazarotene induced) 3 [Sour
7	10537	-1.63	2e-16	1e-15	50 x 1 ubiquitin D [Source:HGNC Symbol;Acc:18795]
8	23643	-1.33	9e-16	1e-13	50 x 3 lymphocyte antigen 96 [Source:HGNC Symbol;Acc:17156]
9	713	-1.3	4e-15	1e-13	50 x 1 complement component 1, q subcomponent, B chain [Source
10	894	-1.29	6e-15	2e-12	50 x 4 cyclin D2 [Source:HGNC Symbol;Acc:1583]
11	3128	-1.24	6e-14	2e-12	50 x 1 major histocompatibility complex, class II, DR beta 6 (pseudo
12	241	-1.23	1e-13	2e-12	50 x 1 arachidonate 5-lipoxygenase-activating protein [Source:HG]
13	919	-1.22	2e-13	1e-11	50 x 1 CD247 molecule [Source:HGNC Symbol;Acc:1677]
14	397	-1.18	5e-13	2e-10	50 x 1 Rho GDP dissociation inhibitor (GDI) beta [Source:HGNC Syr
15	915	-1.14	5e-12	3e-10	49 x 1 CD3d molecule, delta (CD3-TCR complex) [Source:HGNC S
16	6451	-1.11	2e-11	3e-10	50 x 5 SH3 domain binding glutamic acid-rich protein like [Source:H
17	260436	-1.11	2e-11	3e-10	50 x 1 follicular dendritic cell secreted protein [Source:HGNC Symbc
18	1396	-1.1	3e-11	3e-10	50 x 5 cysteine-rich protein 1 (intestinal) [Source:HGNC Symbol;Ac
19	3936	-1.09	4e-11	3e-10	50 x 1 lymphocyte cytosolic protein 1 (L-plastin) [Source:HGNC Syr
20	3001	-1.09	4e-11	2e-09	48 x 1 granzyme A (granzyme 1, cytotoxic T-lymphocyte-associat

Local Geneset Analysis

Underexpression

Rank	GSZ	p-value	#in/all	Geneset
1	-43.1	NULL	12 / 15	CC MHC class II protein complex
2	-26.08	NULL	3 / 6	GSEA C2SANA_RESPONSE_TO_IFNG_UP
3	-26.04	NULL	15 / 47	BP antigen processing and presentation
4	-25.66	NULL	91 / 417	H.Tiss WIRTH_Immune system
5	-22.71	NULL	53 / 312	BP immune response
6	-22.57	NULL	7 / 21	CC clathrin-coated endocytic vesicle membrane
7	-21.48	NULL	7 / 23	CC integral to luminal side of endoplasmic reticulum membrane
8	-20.41	NULL	2 / 4	MMML C6SICIEJ_MMML 2
9	-20.13	NULL	15 / 60	BP T cell costimulation
10	-19.77	NULL	96 / 553	Cancer Lembecke_Colonc Inflammation
11	-19.27	NULL	7 / 28	CC transport vesicle membrane
12	-18.33	NULL	9 / 35	CC trans-Golgi network membrane
13	-17.9	NULL	7 / 32	CC ER to Golgi transport vesicle membrane
14	-17.78	NULL	2 / 6	GSEA C2LUI_THYROID_CANCER_CLUSTER_4
15	-17.72	NULL	2 / 3	GSEA C2KEGG_VIRAL_MYOCARDITIS
16	-17.64	NULL	14 / 87	BP antigen processing and presentation of exogenous peptide antigen
17	-16.56	NULL	4 / 7	Glio Donson-cytotoxic effectors-associated with LTS in HGA
18	-16.25	NULL	2 / 5	GSEA C2WEST_ADRENOCORICAL_CARCINOMA_VS_ADENOMA_DN
19	-16.05	NULL	1 / 2	GSEA C2KEGG_INTESTINAL_IMMUNE_NETWORK_FOR_IGA_PRODUC
20	-16.05	NULL	1 / 2	GSEA C2KEGG_AUTOIMMUNE_THYROID_DISEASE
21	-16.05	NULL	1 / 2	GSEA C2KEGG_SYSTEMIC_LUPUS_ERYTHEMATOSUS
22	-15.99	NULL	5 / 12	GSEA C2BIOCARTA_CTL_PATHWAY
23	-15.87	NULL	9 / 16	GSEA C2FARMER_BREAST_CANCER_CLUSTER_1
24	-15.83	NULL	16 / 84	BP T cell receptor signaling pathway
25	-15.82	NULL	6 / 11	GSEA C2BIOCARTA_TCYTOTOXIC_PATHWAY
26	-15.72	NULL	5 / 12	BP immunoglobulin mediated immune response
27	-15.71	NULL	44 / 265	Glio willscher_GBM_Verhaak-CL_expression_B_up
28	-15.71	NULL	44 / 265	Glio willscher_GBM_Verhaak-MES_expression_B_up
29	-15.71	NULL	44 / 265	Glio willscher_GBM_Verhaak-PNwt_expression_B_down
30	-15.71	NULL	44 / 265	Glio willscher_GBM_Verhaak-PNmut_expression_B_down
31	-15.51	NULL	9 / 46	CC endocytic vesicle membrane
32	-15.49	NULL	8 / 52	Chr Chr HSCHR6_MHC_QBL
33	-15.44	NULL	7 / 15	GSEA C2FINAK_BREAST_CANCER_SDPD_SIGNATURE
34	-15.36	NULL	2 / 4	GSEA C2REACTOME_CLASSICAL_ANTIBODY_MEDIATED_COMPLEMEN
35	-14.95	NULL	2 / 4	GSEA C2KEGG_LEISHMANIA_INFECTION
36	-14.87	NULL	11 / 60	BP interferon-gamma-mediated signaling pathway
37	-14.82	NULL	4 / 8	GSEA C2NIELSEN_SYNOVIAL_SARCOMA_DN
38	-14.5	NULL	5 / 14	GSEA C2WU_SILENCED_BY_METHYLATION_IN_BLADDER_CANCER
39	-14.43	NULL	2 / 6	GSEA C2BUDHU_LIVER_CANCER_METASTASIS_UP
40	-13.96	NULL	3 / 8	GSEA C2INDSTEDT_DENDRITIC_CELL_MATURATION_D

p-values

